Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial - Zolopa, Andrew R.; Berger, Daniel S.; Lampiris, Harry; Zhong, Lijie; Chuck, Steven L.; Enejosa, Jeffrey V.; Kearney, Brian P.; Cheng, Andrew K. (The Journal of infectious diseases, 2010)
Keywords: Adolescent; Adult; Aged; Antivirals; Biological and medical sciences; Biomedical research; CD4 Lymphocyte Count; Darunavir; Dosage; Drug Resistance, Viral - genetics; Drug Therapy, Combination; Female; Fundamental and applied biological sciences. Psychology; HIV; HIV 1; HIV Infections - blood; HIV Infections - drug therapy; HIV Integrase Inhibitors - pharmacology; HIV Integrase Inhibitors - therapeutic use; HIV Protease Inhibitors - pharmacology; HIV Protease Inhibitors - therapeutic use; HIV-1 - drug effects; HIV-1 - genetics; HIV/AIDS; Human immunodeficiency virus; Human immunodeficiency virus 2; Humans; Infectious diseases; Male; Medical research; Medical sciences; Microbiology; Middle Aged; Miscellaneous; Protease inhibitors; Pyridines - pharmacology; Pyridines - therapeutic use; Pyrones - pharmacology; Pyrones - therapeutic use; Quinolones - pharmacology; Quinolones - standards; Quinolones - therapeutic use; Ritonavir - pharmacology; Ritonavir - therapeutic use; RNA; RNA, Viral - blood; Sulfonamides - pharmacology; Sulfonamides - therapeutic use; Treatment Outcome; Virology; Young Adult; Virus; Infection; Resistance; Antiretroviral agent; Integrase inhibitor; HIV-1 virus; Retroviridae; Antiviral; Elvitegravir; Clinical trial; Human immunodeficiency virus; Lentivirus